Fludarabine
Juvenile Myelomonocytic Leukemia
Children's Oncology GroupSmall moleculePhase 3Active
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Juvenile Myelomonocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 4 | BBB |
Thiotepa St. Jude Children's Research Hospital | Phase 3 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 4 | BBB |
FILGRASTIM Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
CYCLOSPORIN A Case Comprehensive Cancer Center | Phase 3 | BB |
View all 46 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →